Fibrinolytic crosstalk with endothelial cells expands murine mesenchymal stromal cells

Blood

Volumn 128, Issue 8, 2016, Pages 1063-1075

  Dhahri, Douaa ^a,b   Sato Kusubata, Kaori ^a,b   Ohki Koizumi, Makiko ^a,b   Nishida, Chiemi ^a,b   Tashiro, Yoshihiko ^a,b   Munakata, Shinya ^a,b   Shimazu, Hiroshi ^a,b   Salama, Yousef ^a,b   Eiamboonsert, Salita ^a,b   Nakauchi, Hiromitsu ^a,b   Hattori, Koichi ^a,b   Heissig, Beate ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; CD45 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; GELATINASE B; PLASMINOGEN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BB; STEM CELL ANTIGEN 1; STEM CELL FACTOR; ATAXIN 1; SIGNAL PEPTIDE; STEM CELL FACTOR RECEPTOR; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MEGADOSE; FIBRINOLYSIS; HUMAN; HUMAN CELL; IN VIVO STUDY; LOW DRUG DOSE; MESENCHYMAL STROMA CELL; MOUSE; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; STEM CELL EXPANSION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; ANIMAL; BONE MARROW; C57BL MOUSE; CELL PROLIFERATION; COCULTURE; CYTOLOGY; DRUG EFFECTS; ENDOTHELIUM CELL; METABOLISM;

ANIMALS; ANTIGENS, CD45; ATAXIN-1; BONE MARROW; CELL PROLIFERATION; COCULTURE TECHNIQUES; ENDOTHELIAL CELLS; FIBRINOLYSIS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MATRIX METALLOPROTEINASE 9; MESENCHYMAL STROMAL CELLS; MICE, INBRED C57BL; PLASMINOGEN; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; STEM CELL FACTOR; TISSUE PLASMINOGEN ACTIVATOR; UP-REGULATION;

EID: 84984699249     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-10-673103     Document Type: Article

References (44)

1. Heissig B, Dhahri D, Eiamboonsert S, et al. Role of mesenchymal stem cell-derived fibrinolytic factor in tissue regeneration and cancer progression. Cell Mol Life Sci. 2015;72(24): 4759-4770.
2. Latsinik NV, Luria EA, Friedenstein AJ, Samoylina NL, Chertkov IL. Colony-forming cells in organ cultures of embryonal liver. J Cell Physiol. 1970; 75(2):163-165.
3. Friedenstein AJ. Stromal mechanisms of bone marrow: cloning in vitro and retransplantation in vivo. Haematol Blood Transfus. 1980;25:19-29.
4. Horwitz EM, Le Blanc K, Dominici M, et al; International Society for Cellular Therapy. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy. 2005;7(5):393-395.
5. Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell. 2008;2(4):313-319.
6. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cellbased therapies. Tissue Eng. 2001;7(2):211-228.
7. Young HE, Steele TA, Bray RA, et al. Human reserve pluripotent mesenchymal stem cells are present in the connective tissues of skeletal muscle and dermis derived from fetal, adult, and geriatric donors. Anat Rec. 2001;264(1):51-62.
8. Toma JG, Akhavan M, Fernandes KJ, et al. Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nat Cell Biol. 2001; 3(9):778-784.
9. Fukuchi Y, Nakajima H, Sugiyama D, Hirose I, Kitamura T, Tsuji K. Human placenta-derived cells have mesenchymal stem/progenitor cell potential. Stem Cells. 2004;22(5):649-658.
10. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999; 284(5411):143-147.
11. Crisan M, Yap S, Casteilla L, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 2008;3(3): 301-313.
12. Sacchetti B, Funari A, Michienzi S, et al. Selfrenewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell. 2007;131(2):324-336.
13. Méndez-Ferrer S, Michurina TV, Ferraro F, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010; 466(7308):829-834.
14. Zhou BO, Yue R, Murphy MM, Peyer JG, Morrison SJ. Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell. 2014;15(2):154-168.
15. Morikawa S, Mabuchi Y, Kubota Y, et al. Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. J Exp Med. 2009; 206(11):2483-2496.
16. Matsuzaki Y, Mabuchi Y, Okano H. Leptin receptor makes its mark on MSCs. Cell Stem Cell. 2014;15(2):112-114.
17. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kitligand. Cell. 2002;109(5):625-637.
18. Heissig B, Lund LR, Akiyama H, et al. The plasminogen fibrinolytic pathway is required for hematopoietic regeneration. Cell Stem Cell. 2007; 1(6):658-670.
19. Cauwe B, Van den Steen PE, Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol. 2007;42(3):113-185.
20. Heissig B, Ohki-Koizumi M, Tashiro Y, Gritli I, Sato-Kusubata K, Hattori K. New functions of the fibrinolytic system in bone marrow cell-derived angiogenesis. Int J Hematol. 2012;95(2):131-137.
21. Nishida C, Kusubata K, Tashiro Y, et al. MT1-MMP plays a critical role in hematopoiesis by regulating HIF-mediated chemokine/cytokine gene transcription within niche cells. Blood. 2012; 119(23):5405-5416.
22. Sato A, Nishida C, Sato-Kusubata K, et al. Inhibition of plasmin attenuates murine acute graft-versus-host disease mortality by suppressing the matrix metalloproteinase-9-dependent inflammatory cytokine storm and effector cell trafficking. Leukemia. 2015;29(1): 145-156.
23. Heissig B, Ohki M, Ishihara M, et al. Contribution of the fibrinolytic pathway to hematopoietic regeneration. J Cell Physiol. 2009;221(3): 521-525.
24. Wang X, Lee SR, Arai K, et al. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med. 2003;9(10):1313-1317.
25. Rifkin DB, Mazzieri R, Munger JS, Noguera I, Sung J. Proteolytic control of growth factor availability. APMIS. 1999;107(1):80-85.
26. Fredriksson L, Li H, Fieber C, Li X, Eriksson U. Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J. 2004;23(19):3793-3802.
27. Dean RA, Cox JH, Bellac CL, Doucet A, Starr AE, Overall CM. Macrophage-specific metalloelastase (MMP-12) truncates and inactivates ELR+ CXC chemokines and generates CCL2, -7, -8, and -13 antagonists: potential role of the macrophage in terminating polymorphonuclear leukocyte influx. Blood. 2008;112(8):3455-3464.
28. Ng F, Boucher S, Koh S, et al. PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood. 2008;112(2): 295-307.
29. Rodrigues M, Blair H, Stockdale L, Griffith L, Wells A. Surface tethered epidermal growth factor protects proliferating and differentiating multipotential stromal cells from FasL-induced apoptosis. Stem Cells. 2013;31(1):104-116.
30. Itkin T, Ludin A, Gradus B, et al. FGF-2 expands murine hematopoietic stem and progenitor cells via proliferation of stromal cells, c-Kit activation, and CXCL12 down-regulation. Blood. 2012; 120(9):1843-1855.
31. Tokunaga A, Oya T, Ishii Y, et al. PDGF receptor beta is a potent regulator of mesenchymal stromal cell function. J Bone Miner Res. 2008;23(9): 1519-1528.
32. Tamplin OJ, Durand EM, Carr LA, et al. Hematopoietic stem cell arrival triggers dynamic remodeling of the perivascular niche. Cell. 2015; 160(1-2):241-252.
33. Tashiro Y, Nishida C, Sato-Kusubata K, et al. Inhibition of PAI-1 induces neutrophil-driven neoangiogenesis and promotes tissue regeneration via production of angiocrine factors in mice. Blood. 2012;119(26):6382-6393.
34. Ohki M, Ohki Y, Ishihara M, et al. Tissue type plasminogen activator regulates myeloid-cell dependent neoangiogenesis during tissue regeneration. Blood. 2010;115(21):4302-4312.
35. Herbert JM, Lamarche I, Prabonnaud V, Dol F, Gauthier T. Tissue-type plasminogen activator is a potent mitogen for human aortic smooth muscle cells. J Biol Chem. 1994;269(4):3076-3080.
36. Nissen LJ, Cao R, Hedlund EM, et al. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest. 2007;117(10): 2766-2777.
37. Ibrahim AA, Yahata T, Onizuka M, et al. Inhibition of plasminogen activator inhibitor type-1 activity enhances rapid and sustainable hematopoietic regeneration. Stem Cells. 2014;32(4):946-958.
38. D'Andrea FP, Horsman MR, Kassem M, Overgaard J, Safwat A. Tumourigenicity and radiation resistance of mesenchymal stem cells. Acta Oncol. 2012;51(5):669-679.
39. Sugrue T, Lowndes NF, Ceredig R. Mesenchymal stromal cells: radio-resistant members of the bone marrow. Immunol Cell Biol. 2013;91(1):5-11.
40. Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature. 2012; 481(7382):457-462.
41. Rafii S, Butler JM, Ding B-S. Angiocrine functions of organ-specific endothelial cells. Nature. 2016; 529(7586):316-325.
42. Ornitz DM, Marie PJ. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev. 2002;16(12):1446-1465.
43. Coutu DL, François M, Galipeau J. Inhibition of cellular senescence by developmentally regulated FGF receptors in mesenchymal stem cells. Blood. 2011;117(25):6801-6812.
44. Xu J, Wang W, Ludeman M, et al. Chondrogenic differentiation of human mesenchymal stem cells in three-dimensional alginate gels. Tissue Eng Part A. 2008;14(5):667-680.